(Reuters) - The FDA earlier this year asked Sanofi to give it more
information about how it is conducting analysis in its U.S.
laboratory on the part of the drug that targets whooping cough
after the vaccine maker moved the analysis from its lab in
Toronto, Canada.
"It's a technical matter. The vaccine itself is not being
questioned," a Sanofi-Pasteur spokesman said.
Read more at Reuters.com Government Filings News
information about how it is conducting analysis in its U.S.
laboratory on the part of the drug that targets whooping cough
after the vaccine maker moved the analysis from its lab in
Toronto, Canada.
"It's a technical matter. The vaccine itself is not being
questioned," a Sanofi-Pasteur spokesman said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment